Health & Environmental Research Online (HERO)


Print Feedback Export to File
2749865 
Journal Article 
Pharmacokinetics of ciprofloxacin in impaired liver function 
Esposito, S; Miniero, M; Barba, D; Sagnelli, E 
1989 
Yes 
International Journal of Clinical Pharmacology Research
ISSN: 0251-1649 
IPA/90/891188 
J 
REF 12 
37-41 
English 
2707924 
IPA COPYRIGHT: ASHP The pharmacokinetics of ciprofloxacin (I) after a single 500 mg oral dose were studied in 7 healthy volunteers (4 males; median age 36 yr) and 19 patients (11 males; median age 50 yr) with liver cirrhosis. No significant differences were noticed in Cmax, Tmax, T1/2, and AUCtot in patients with mild to moderate liver impairment and in the control group. However, patients with more severe liver impairment showed a Cmax 15 to 25% higher than in other groups, a T1/2 1.12 to 1.42 h longer than in other groups and a consequent much higher AUCtot. The concomitant administration of diuretics or anti-H2 drugs was also evaluated as a possible factor affecting I pharmacokinetics, but no significant differences were noted. It was concluded that a mild or moderate impairment of liver function did not affect the pharmacokinetics of I, but severe liver impairment could affect its Cmax and serum half-life, so that further multiple doses will be needed to evaluate if any dosage adjustment would be required in these patients.